Business Wire

Philip Morris International: Why World No Tobacco Day Should Be World No Smoking Day

Jaa

Philip Morris International (PMI) will mark World No Tobacco Day with a call to recognize this day as “World No Smoking Day.” PMI is publishing informational advertisements highlighting that people who smoke deserve the opportunity to learn about smoke-free alternatives to cigarettes.

It is clear that despite the well-known health risks associated with smoking, many people continue to smoke. The World Health Organization (WHO) predicts that there will be more than 1 billion people who smoke in 2025, about the same number as today. Their best choice would be to quit—but many don’t. It makes sense that these men and women should have access to and information about less-harmful alternatives to cigarettes. Why would anyone deny them this opportunity? PMI is calling for an additional, bold approach to public health.

“For people who will otherwise continue to smoke, WHO is in the perfect position to drive switching from cigarettes to sensible alternatives. A policy that informs people about those alternatives—in essence, a World No Smoking Day—would reduce smoking prevalence to a far greater extent and at a much faster rate than the existing suite of tobacco-control measures alone,” said André Calantzopoulos, PMI's Chief Executive Officer. “People who smoke deserve a sensible plan that takes full account of better alternatives to cigarettes. For our part, we’re determined to deliver a smoke-free future through innovations that stand up to scientific scrutiny and that meet consumer needs.”

PMI has already committed $4.5bn in supporting a team of 400 world-class scientists, engineers and technicians who have spent years creating and testing a range of smoke-free products that offer a much better choice for the millions of smokers who don’t quit. More than 5 million smokers worldwide have already completely abandoned cigarette smoking and switched to IQOS, PMI’s heated tobacco product, with 10,000 smokers switching every single day. And PMI is not the only company pursuing innovation as important to the world’s 1 billion smokers worldwide—the tobacco industry generally is beginning to move in this direction, to the benefit of men and women who smoke.

“Our short-term ambition is that one out of three of our consumers, 40 million men and women who smoke, will have switched to better alternatives by 2025. Ultimately, we want to be in a position to stop selling cigarettes entirely. However, we need the support of governments and the public health community to make this happen in as short a time as possible. I believe that instead of just designating one day as World No Tobacco Day, we should promote every day as World No Smoking Day,” said Calantzopoulos.

PMI is proposing that governments and authorities investigate thoroughly how scientifically substantiated smoke-free products can be used as a complementary public health strategy alongside smoking prevention and cessation. With appropriate government control and oversight, these products can have a meaningful and positive impact on public health.

To learn more about PMI’s views on World No Tobacco Day, visit http://www.pmi.com/world-no-smoking-day-2018. PMI commenced publication in national and international media on May 30-31.

Philip Morris International: Who We Are

We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products that are a much better choice than continuing to smoke cigarettes. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirements. Our vision is that these products ultimately replace cigarettes to the benefit of adult smokers, society, our company and our shareholders. For more information, see our PMI and PMIScience websites.

Contact information

Media enquiries
Philip Morris International media office
T: +41 (0)58 242 4500
E: Ryan.Sparrow@pmi.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy21.5.2019 08:00:00 EESTTiedote

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005695/en/ Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2. Presently, RAASi treatment is frequently discontinued due to the risk of hyperkalaemia (elevated blood potassium levels). The DIAMOND study is designed to further support the use of Veltassa® to effectively control high blood potassium levels, thereby enabling optimal RAASi therapy in HF patients. It is a global, multicentre, double-blind, placebo-controlled trial aiming to study approximately 2,400 patients in over 400 sites. Eligible patients wil

Concierge Auctions and Engel & Völkers to Sell $29.9 Million New Jersey Estate Without Reserve20.5.2019 20:32:00 EESTTiedote

A 32,507-square-foot Saddle River residence will sell at auction next month via leading global firm Concierge Auctions. Known as “Stone Palace on the Hill,” the home features a glass elevator, tennis court, racquetball court, wine cellar, and two swimming pools. 144 East Saddle River Road was previously listed for $29.9 million and will sell Without Reserve in cooperation with Alina Pogorelova and Lisa Troyano-Ascolese of Engel & Völkers. Bidding, which will be held via Concierge Auctions’ online marketplace, will open on June 21st and close on June 27. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005686/en/ 144 East Saddle River Road | New York Metro, NJ (Photo: Business Wire) “The quality of work and detail that went into building this home is perhaps the most impressive element of the property,” said Troyano-Ascolese. “With astounding details from custom gold-plated and forged-iron railings to a complete hand-cut

CNIM to Optimize Renewable Heat Production for Nantes District Heating20.5.2019 20:20:00 EESTTiedote

CNIM, a French international industrial equipment manufacturer and integrator, has entered into an agreement concerning the energy efficiency optimisation at the waste-to-energy plant serving the cities of Nantes and Saint Nazaire, in the North West of France. Under the terms of this agreement, CNIM will install an absorption heat pump to boost the supply of hot water to Nantes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005678/en/ Heat-Pump_13MW_Brive (c) CNIM The delivery is scheduled for October 2019. The new system has been designed to inject 3.1 MW of heat energy into Nantes' district heating system. 2018: Two contracts to upgrade heat networks in France and Switzerland Prior to this agreement, CNIM won two other major contracts to upgrade the energy efficiency of waste-to-energy plants in France and Switzerland, and to supply district heating networks with renewable energy. Supplying 30 MW to Basel's district

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD120.5.2019 19:46:00 EESTTiedote

Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results show that nintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Patients taking nintedanib showed a 44% reduction in the rate of decline of their lung function, measured in FVC assessed over 52 weeks1. These new data were today published in the New England Journal of Medicine (NEJM) and presented to the medical community at the American Thoracic Society (ATS) International Conference, in Dallas, USA. SENSCIS® is the largest randomised controlled trial to be conducted in patients with SSc-ILD, a disease for which there are currently no approved treatments.1,3,4 Results also showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibro

MyHeritage laajenee terveyteen lanseeramalla uuden DNA-testin, joka tarjoaa kuluttajille yksilöllistä tietoa terveydestä20.5.2019 18:55:00 EESTTiedote

MyHeritage, maailman johtava perhehistoria- ja DNA-testauspalvelu, ilmoitti tänään DNA-tuotevalikoimansa merkittävästä laajenemisesta MyHeritage Terveys+Perimä DNA-testin lanseeraamisen myötä. Testi tarjoaa uuden ulottuvuuden geneettiseen tietoon kattavien terveysraporttien avulla, mikä voi vaikuttaa terveys- ja elämäntapavalintoihin tulevaisuudessa. Se on nykyisen MyHeritage Vain-Perimä DNA-testin supersetti ja sisältää sen peruspilarit: etnisen alkuperän prosentuaalisen jakauman ja yhteisen, jaetun DNAn avulla löytyneet sukulaiset. MyHeritage on nyt ainoa maailmanlaajuinen DNA-yritys, joka tarjoaa kuluttajille kattavan terveys- ja perimä-tuotteen yli 40 kielellä. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20190520005590/fi/ MyHeritage laajenee terveyteen lanseeramalla uuden DNA-testin, joka tarjoaa kuluttajille yksilöllistä tietoa terveydestä (Graphic: Business Wire) Terveys+Perimä-tuotteen lanseeraus erottaa MyHerita

Airship Bolsters its Senior Leadership Team for Accelerated Global Growth20.5.2019 16:00:00 EESTTiedote

Customer engagement company Airship today announced four senior leadership appointments including Dale Flores as vice president of sales Americas, Neil Gariepy as vice president of infrastructure and security, David King Harris as vice president of sales EMEA, and Jeff Winsor as vice president of technology services. Dale Flores will lead the rapid expansion of Airship’s Americas sales organization, growing solution adoption to generate greater business value for customers throughout the region. Flores brings two decades of global SaaS sales and customer success management experience to Airship, including over 14 years leading sales teams at Silverpop and IBM. Most recently, Flores was head of customer success at digital customer experience company Clicktale. Neil Gariepy will lead Airship’s customer engineering, infrastructure and security teams, with responsibility for expanding Airship’s infrastructure globally while further optimizing its cost, performance and security. Gariepy bri

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme